Part of US based
Semler Group of Companies,
in business since 1946


YOU ARE HERE: Home News & Events Latest News Latest News Semler Research Center Announces its Strategic Expansion with the Launch of the Asia CRO Alliance
Semler Research Center Announces its Strategic Expansion with the Launch of the Asia CRO Alliance

Semler Research Center announces the expansion of regional operations across Asia with the launch of the ‘Asia CRO Alliance’ (ACA,, the first ever exclusive integrated network of CROs originating from Asia. The ACA currently has presence in six countries and delivery capabilities in fourteen countries across Asia. The goal of this alliance is to promote quality drug development in Asia. ACA combines the cumulative experience and expertise of six leading CROs, Shanghai SLG CRO Co. Ltd. (China), SRD Co.Ltd./SRD International Corp. (Japan), Semler Research Centre Pvt. Ltd. (India), LSK Global Pharma Services Co. Ltd. (South Korea), Veras Research Sdn Bhd (Malaysia) and StatPlus Inc. (Taiwan) to offer a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Asia, home to 60% of the world’s population, offers unique advantages to clinical research besides hosting a thriving pharmaceutical and biotechnology industry. Recent statistics indicate that only 6% of eligible patients in the US actually participate in clinical trials resulting in , 87% of trials in the US failing to complete within time, and this indirectly increases the cost of drug development in the western world. Emerging markets such as Asia offers pharmaceutical companies accelerated patient enrollments along with the regulatory, human resource and IT infrastructure required for conducting clinical trials. Most Asian parts of global clinical trials are either conducted by sponsors directly or by affiliates of multinational CROs with headquarters generally in western countries. This model has been in place for a while, despite challenges such as the central team’s unfamiliarity with local requirements , slow reaction time to issues identified at sites and a larger budget to support the maintenance of regional staff.

ACA offers a unique solution by neutralizing these limitations while preserving the existing advantages of the current global model as each of the ACA partners can spearhead a clinical project and thereby providing the much needed, ‘One stop solution’ to sponsors. The quality and efficiency of conducting multinational trials are supported by a framework of robust harmonized processes, an empowered management team, well trained project management staff with the expertise to anticipate and manage local challenges.and at a significant cost advantage due to lower overheads.

Speaking on the strengths of the alliance, Dr. Jayanti Gupta, Vice President (Clinical Development), Semler Research Center and ACA board member said, "ACA will provide a robust platform to our customers to accelerate their drug development programs by leveraging the ‘Asia advantage’ with superior quality at competitive costs. The alliance includes countries like Japan and Korea, which have always been important pharma markets; countries of emerging importance such as India and China, as well as countries that offer significant drug development advantages such as Taiwan and Malaysia. With this alliance, we continue our strategic expansion into key geographies around the world.”

Even as the ACA formally launches with delivery spread over fourteen countries, further expansion to cover the entire Asia-Pacific region has been envisaged as the next immediate step, offering global clients the “Asia Pacific advantage”.

Media contact details
Umesh BA (Vice President – Corporate Development),
Semler Research Center (SRC),
+91 (80) 42627203/+91 98450 90365,
This e-mail address is being protected from spambots. You need JavaScript enabled to view it




Quick Contact

INDIA Tel: +91 80 4262 7200

US Tel: +1 818 760 1000